The oncology world is awash with a steady flow of new and exciting biologic agents and targeted immune therapies. Chimeric antigen receptor T cells are a new class of “living drugs” that are designed to reprogram T cells to target and kill tumor cells upon contact. Chimeric antigen receptor T cell treatment has yielded impressive results with respect to overall response rates and complete remission rates in patients with multiply relapsed and resistant leukemia and lymphoma. Drugs that target and inhibit the anaplastic lymphoma kinase inhibitor and poly-ADP ribose polymerase inhibitor pathways are extending progression-free survival in subsets of patients with non-small cell lung cancer and ovarian tumors who harbor these mutations, respectively.
SadelainMRiviereIRiddellS.Therapeutic T cell engineering. Nature2017; 545: 423–431.
2.
ZhaoZCondominesMvan der StegenSJCet al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell2015; 28(4): 415–428.
3.
SadelainMBrentjensRRiviereI.The basic principles of chimeric antigen receptor design. Cancer Discov2013; 3(4): 388–398.
4.
MausMVThomasAKLeonardDGet al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol2002; 20(2): 143–148.
5.
ShufordWWKlussmanKTritchlerDDet al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med1997; 186(1): 47–55.
6.
SchusterSJ.CD19-directed CAR T cells gain traction. Lancet Oncol2019; 20(1): 2–3.
7.
HartmannJSchussler-LenzMBondanzaAet al. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med2017; 9(9): 1183–1197.
8.
NeelapuSSLockeFLBartlettNLet al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med2017; 377(26): 2531–2544.
9.
US Food and Drug Administration (FDA). Approved cellular and gene therapy products: Yescarta (axicabtagene ciloleucel). Silver Spring, MD: FDA, 2017.
10.
US Food and Drug Administration (FDA). Approved cellular and gene therapy products: Kymriah (tisagenlecleucel). Silver Spring, MD: FDA, 2018.
11.
SchusterSJBishopMRTamCSet al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med2019; 380: 45–56.
12.
LockeFLGhobadiAJacobsonCAet al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol2019; 20(1): 31–42.
13.
MaudeSLBarrettDTeacheyDTet al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J2014; 20(2): 119–122.
14.
HayKAHanafiLALiDet al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood2017; 130(21): 2295–2306.
15.
TeacheyDTLaceySFShawPAet al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov2016; 6(6): 664–679.
16.
NeelapuSSTummalaSKebriaeiPet al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol2018; 15(1): 47–62.
17.
ShawATKimDWNakagawaKet al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med2013; 368: 2385–2394.
18.
SolomonBJMokTKimDWet al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med2014; 371: 2167–2177.
19.
KatayamaRShawATKhanTMet al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med2012; 4(120): 120ra17.
20.
KatayamaRKobayashiYFribouletLet al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res2015; 21(1): 166–174.
21.
ShawATEngelmanJA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med2014; 370: 2537–2539.
22.
GadgeelSMGandhiLRielyGJet al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol2014; 15(10): 1119–1128.
23.
CamidgeDRKimHRAhnMJet al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med2018; 379(21): 2027–2039.
24.
BrosnanEMWeickhardtAJLuXet al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer2014; 120(5): 664–674.
25.
SetoTKiuraKNishioMet al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol2013; 14(7): 590–598.
26.
ArakawaHOmoteSTamaiI.Inhibitory effect of crizotinib on creatinine uptake by renal secretory transporter OCT2. J Pharm Sci2017; 106(9): 2899–2903.
27.
CamidgeDRBrosnanEMDeSilvaCet al. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol2014; 9(11): 1634–1637.
28.
HalpennyDFMcEvoySLiAet al. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer—incidence, radiological features and clinical characteristics. Lung Cancer2017; 106: 33–36.
29.
CameronLBJiangDHMoodieKet al. Crizotinib associated renal cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging2017; 17: 7.
30.
SchnellPBartlettCHSolomonBJet al. Complex renal cysts associated with crizotinib treatment. Cancer Med2015; 4: 887–896.
31.
LinYTWangYFYangJCet al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol2014; 9(11): 1720–1725.
32.
OkuboKSatoANakamotoKet al. Bosniak category III renal cysts caused by crizotinib in an anaplastic lymphoma kinase gene-rearranged non-small cell lung cancer patient. Urology2018; 121: e3–e4.
33.
TaimaKTanakaHTanakaYet al. Regression of crizotinib-associated complex cystic lesions after switching to alectinib. Intern Med2017; 56(17): 2321–2324.
34.
YoneshimaYOkamotoIArimura-OmoriMet al. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement. Invest New Drugs2015; 33(2): 510–512.
35.
O’CearbhaillRE.Using PARP inhibitors in advanced ovarian cancer. Oncology2018; 32(7): 339–343.
36.
US Food and Drug Administration (FDA). Approved drug therapy Rubraca (rucaparib). Silver Spring, MD: FDA, 2016.
37.
US Food and Drug Administration (FDA). Approved drug therapy Lynparza (olaparib). Silver Spring, MD: FDA, 2016.
38.
KaufmanBShapira-FrommerRSchmutzlerRKet al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol2015; 33: 244–250.
39.
DomchekSMAghajanianCShapira-FrommerRet al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol2016; 140(2): 199–203.
40.
KayeSBLubinskiJMatulonisUet al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol2012; 30: 372–379.
41.
DrewYLedermannJHallGet al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer2016; 114: 723–730.
42.
LedermannJHarterPGourleyCet al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med2012; 366: 1382–1392.
43.
Pujade-LauraineELedermannJASelleFet al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol2017; 18(9): 1274–1284.
44.
ColemanRLOzaAMLorussoDet al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017; 390(10106): 1949–1961.
45.
SalahudeenAKDoshiSMPawarTet al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol2013; 8(3): 347–354.
